Replies to post #54605 on NorthWest Biotherapeutics Inc (NWBO)

[DoGood_DoWell]

Or like chum in front of sharks, or sushi in front of my kids:-)

[Doktornolittle]

Oh... I left out the screening hold as one of the reasons for the recent SP decline. That is a big one to leave out.

I don't remember the order of these major events. I should sit down and try to draw that up, for my own sake. Wish I was an iHub member. It would make such research much easier. But it can be done. And of course many will know the sequence of such major things off the top of their heads. Not me though.

[Doktornolittle]

"Wasn't the patent issue something that was done long before the screening hold? Is protecting the patents and hence the company, a bad thing? I rather like the fact that they are not dangling like cheese in front of the aggressive mice."

Your right that the patent positioning was many years ago. I didn't know that. The only reason it recently got attention was because it was a section of Phase V.

According to Phase V there were 32 patents that got shuffled around, some in 2004, and some in 2012, with 26 that remain outside of NWBO, in the hands of Dennis Mehiel.

To me it looks like the patents may have been used as collateral in loans. There was speculation on the board that these may have been key patents, but I do not remember anyone studying which patents were involved to verify that. Maybe the patents are collateral and they deliberately used patents that might be valuable to some, but not to NWBO.

What Phase V fails to mention is that NWBO owns on the order of 200 patents. So these 26 may or may not be of importance. They do not support the idea that they are important. Most smallcap biotech stocks have only a handfull of patents. This is not exactly a weak area for NWBO, yet Phase V paints the picture that it is in shambles. Again, it is possible this is an issue, if these are key patents, but there is no reason to assume that, and there is no support for that view provided by Phase V.